Intuitive Surgical, Inc. (NASDAQ:ISRG) Director Sells $2,626,191.00 in Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) Director Amal M. Johnson sold 4,635 shares of the firm’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $566.60, for a total value of $2,626,191.00. Following the transaction, the director now owns 12,275 shares of the company’s stock, valued at $6,955,015. This trade represents a 27.41 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Intuitive Surgical Stock Performance

Shares of ISRG opened at $580.18 on Friday. The stock has a 50 day simple moving average of $549.32 and a 200 day simple moving average of $507.50. Intuitive Surgical, Inc. has a 52-week low of $364.17 and a 52-week high of $616.00. The firm has a market capitalization of $206.65 billion, a PE ratio of 93.28, a P/E/G ratio of 5.19 and a beta of 1.39.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Berbice Capital Management LLC acquired a new position in Intuitive Surgical in the 4th quarter worth $26,000. Godsey & Gibb Inc. boosted its position in shares of Intuitive Surgical by 140.0% during the third quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 35 shares during the period. MidAtlantic Capital Management Inc. bought a new position in shares of Intuitive Surgical during the third quarter worth about $33,000. Decker Retirement Planning Inc. acquired a new stake in Intuitive Surgical in the 4th quarter valued at approximately $36,000. Finally, Capital Performance Advisors LLP bought a new stake in Intuitive Surgical in the 3rd quarter valued at approximately $38,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ISRG. Bernstein Bank raised their price objective on shares of Intuitive Surgical from $655.00 to $700.00 and gave the stock an “overweight” rating in a report on Monday. Piper Sandler reissued an “overweight” rating and issued a $670.00 price objective (up previously from $538.00) on shares of Intuitive Surgical in a research note on Friday, January 24th. JPMorgan Chase & Co. raised their target price on Intuitive Surgical from $575.00 to $675.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. UBS Group upped their price target on shares of Intuitive Surgical from $500.00 to $560.00 and gave the stock a “neutral” rating in a research report on Monday. Finally, Stifel Nicolaus raised their price objective on shares of Intuitive Surgical from $525.00 to $610.00 and gave the company a “buy” rating in a research report on Thursday, December 5th. One research analyst has rated the stock with a sell rating, five have given a hold rating and sixteen have given a buy rating to the company. According to MarketBeat.com, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and an average price target of $613.10.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.